

WDR42A Antibody (monoclonal) (M01A)

Mouse monoclonal antibody raised against a full length recombinant WDR42A. Catalog # AT4532a

Product Information

Application WB **Primary Accession** Q5TAQ9 **Other Accession** BC0<u>13107</u> Reactivity Human Host mouse Clonality monoclonal Isotype IgM kappa **Clone Names** 1A12 **Calculated MW** 66852

Additional Information

Gene ID 50717

Other Names DDB1- and CUL4-associated factor 8, WD repeat-containing protein 42A,

DCAF8, H326, WDR42A

Target/Specificity WDR42A (AAH13107, 1 a.a. ~ 273 a.a) full-length recombinant protein with

GST tag. MW of the GST tag alone is 26 KDa.

Dilution WB~~1:500~1000

Format Clear, colorless solution in phosphate buffered saline, pH 7.2.

Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions WDR42A Antibody (monoclonal) (M01A) is for research use only and not for

use in diagnostic or therapeutic procedures.

Background


This gene encodes a WD repeat-containing protein that interacts with the Cul4-Ddb1 E3 ligase macromolecular complex. Multiple alternatively spliced transcript variants have been found for this gene.

References

An empirical framework for binary interactome mapping. Venkatesan K, et al. Nat Methods, 2009 Jan. PMID 19060904. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Angers S, et al. Nature, 2006 Oct 5. PMID 16964240. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Jin J, et al. Mol Cell, 2006 Sep 1.

PMID 16949367. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Kimura K, et al. Genome Res, 2006 Jan. PMID 16344560. Towards a proteome-scale map of the human protein-protein interaction network. Rual JF, et al. Nature, 2005 Oct 20. PMID 16189514.

Images



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.